Associations - EGFR G719S

BIOMARKER:

EGFR G719S

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

EGFR G719S EGFR G719S	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR G719S EGFR G719S	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR G719S EGFR G719S	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3
EGFR G719S EGFR G719S	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4
EGFR G719S EGFR G719S	Colon Cancer Colon Cancer	ABP 494 (cetuximab biosimilar) Sensitive: D – Preclinical ABP 494 (cetuximab biosimilar) Sensitive : D
EGFR G719S EGFR G719S	Colon Cancer Colon Cancer	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D
EGFR G719S EGFR G719S	Colon Cancer Colon Cancer	panitumumab Sensitive: D – Preclinical panitumumab Sensitive : D